Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy.

Cho NH, Cheong TC, Min JH, Wu JH, Lee SJ, Kim D, Yang JS, Kim S, Kim YK, Seong SY.

Nat Nanotechnol. 2011 Sep 11;6(10):675-82. doi: 10.1038/nnano.2011.149.

PMID:
21909083
2.

Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.

Osada T, Nagaoka K, Takahara M, Yang XY, Liu CX, Guo H, Roy Choudhury K, Hobeika A, Hartman Z, Morse MA, Lyerly HK.

J Immunother. 2015 May;38(4):155-64. doi: 10.1097/CJI.0000000000000075.

PMID:
25839441
3.

Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli.

Bae MY, Cho NH, Seong SY.

Clin Exp Immunol. 2009 Jul;157(1):128-38. doi: 10.1111/j.1365-2249.2009.03943.x.

5.

Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Nakamori M, Ueda K, Naka T, Ishida K, Primus FJ, Yamaue H.

Int J Cancer. 2007 Feb 1;120(3):585-93.

6.

Immunotherapy with dendritic cells for cancer.

Ballestrero A, Boy D, Moran E, Cirmena G, Brossart P, Nencioni A.

Adv Drug Deliv Rev. 2008 Jan 14;60(2):173-83. Epub 2007 Oct 5. Review.

PMID:
17977615
7.

Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.

Saha A, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M.

Immunology. 2006 Aug;118(4):483-96. Erratum in: Immunology. 2006 Sep;119(1):143.

8.

Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.

Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M.

Cancer Res. 2004 Jul 15;64(14):4995-5003.

9.

Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine.

Wu Y, Wan T, Zhou X, Wang B, Yang F, Li N, Chen G, Dai S, Liu S, Zhang M, Cao X.

Cancer Res. 2005 Jun 1;65(11):4947-54.

10.

The utility of poly(γ-glutamic acid) nanoparticles as antigen delivery carriers in dendritic cell-based cancer immunotherapy.

Matsuo K, Ishii Y, Matsuo K, Yoshinaga T, Akashi M, Mukai Y, Yoshioka Y, Okada N, Nakagawa S.

Biol Pharm Bull. 2010;33(12):2003-7.

11.

Biological properties of dendritic cells: implications to their use in the treatment of cancer.

van Schooten WC, Strang G, Palathumpat V.

Mol Med Today. 1997 Jun;3(6):254-60. Review.

PMID:
9211416
12.

Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.

Lesterhuis WJ, De Vries IJ, Schreibelt G, Schuurhuis DH, Aarntzen EH, De Boer A, Scharenborg NM, Van De Rakt M, Hesselink EJ, Figdor CG, Adema GJ, Punt CJ.

Anticancer Res. 2010 Dec;30(12):5091-7.

PMID:
21187495
13.

Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.

Ishida A, Tanaka H, Hiura T, Miura S, Watanabe S, Matsuyama K, Kuriyama H, Tanaka J, Kagamu H, Gejyo F, Yoshizawa H.

Scand J Immunol. 2007 Nov;66(5):546-54.

14.

Current status and future applications of cellular therapies for cancer.

Copier J, Bodman-Smith M, Dalgleish A.

Immunotherapy. 2011 Apr;3(4):507-16. doi: 10.2217/imt.11.18. Review.

PMID:
21463192
15.

Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response.

Li H, Li Y, Jiao J, Hu HM.

Nat Nanotechnol. 2011 Sep 18;6(10):645-50. doi: 10.1038/nnano.2011.153.

16.
17.

Dendritic-cell-based therapeutic cancer vaccines.

Palucka K, Banchereau J.

Immunity. 2013 Jul 25;39(1):38-48. doi: 10.1016/j.immuni.2013.07.004. Review.

18.

Targeting dendritic cells with antigen-containing liposomes: antitumour immunity.

Altin JG, van Broekhoven CL, Parish CR.

Expert Opin Biol Ther. 2004 Nov;4(11):1735-47. Review.

PMID:
15500402
19.

Understanding and activating immunity against human cancer.

Stevenson FK, Palucka K.

Curr Opin Immunol. 2010 Apr;22(2):212-4. doi: 10.1016/j.coi.2010.03.001. Epub 2010 Mar 24. No abstract available.

20.

Dendritic cell activation kinetics and cancer immunotherapy.

Bellone M, Camporeale A, Boni A.

J Immunol. 2004 Mar 1;172(5):2727-8. No abstract available.

Supplemental Content

Support Center